







an Open Access Journal by MDPI

# **New Insights on Canine Visceral Leishmaniasis**

Guest Editors:

## Dr. Rodolfo Cordeiro Giunchetti

Laboratório de Biologia das Interações Celulares, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil

### Dr. Reysla Maria da Silveira Mariano

Graduate Program in Cell Biology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Deadline for manuscript submissions:

closed (1 December 2023)

## **Message from the Guest Editors**

Leishmaniasis is a group of infectious and parasitic diseases caused by protozoa of the genus *Leishmania*. Leishmaniasis manifests a wide clinical spectrum, and among them, visceral leishmaniasis (VL) is the most severe form. VL caused by *Leishmania infantum* (sin. *Leishmania chagasi*) is a zoonosis whose main urban reservoir is the dog (*Canis familiaris*). Importantly, cases of canine visceral leishmaniasis (CVL) precede HVL cases, emphasizing the important role of dogs in the urban parasite transmission cycle.

Diagnostic method improvements are required in addition to immunoprophylactic approaches that is the main rational strategy to control the human and canine VL. Moreover, additional challenges are the new treatments and predictive disease biomarker studies regarding the CVL resistance and susceptibility outcome.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Hinh Ly

Department of Veterinary & Biomedical Sciences, University of Minnesota, Twin Cities, MN, USA

## **Message from the Editor-in-Chief**

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

**Journal Rank:** JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

#### **Contact Us**